Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States

被引:10
|
作者
Jiang, Yiling [1 ]
Sarpong, Eric M. [2 ]
Sears, Pamela [2 ]
Obi, Engels N. [2 ]
机构
[1] Merck Sharp & Dohme UK Ltd, 120 Moorgate, London EC2Y 9AL, England
[2] Merck & Co Inc, 200 Galloping Hill Rd, Kenilworth, NJ 07033 USA
关键词
Budget impact; Clostridioides difficile; Fidaxomicin; Hospital; Recurrence; Vancomycin; CLINICAL-PRACTICE GUIDELINES; HEALTH-CARE EPIDEMIOLOGY; HOSPITALIZED ADULTS; COST-EFFECTIVENESS; DISEASES SOCIETY; UPDATE;
D O I
10.1007/s40121-021-00480-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction Fidaxomicin is as effective as vancomycin in treating Clostridioides difficile infection (CDI) but more effective at preventing recurrence. However, because fidaxomicin is more costly than vancomycin, its overall value in managing CDI is not well understood. This study assessed the budget impact of introducing fidaxomicin versus vancomycin for the treatment of adults with CDI from a hospital perspective in the US. Methods A cohort-based decision analytic model was developed over a 1-year horizon. A hospital with 10,000 annual hospitalizations was simulated. The model considered two adult populations: patients with no prior CDI episode and patients with one prior CDI episode. Two scenarios were assessed per population: 15% fidaxomicin/85% vancomycin use and 100% vancomycin use. Model inputs were obtained from published sources and expert opinion. Model outcomes included cost, payment, and revenue at the hospital level, per treated CDI patient, and per admitted patient. Budget impact was calculated as the difference in revenue between scenarios. One-way sensitivity analyses tested the effects of varying model inputs on the budget impact. Results In patients with no prior CDI episode, treatment with fidaxomicin resulted in potential savings over 1 year of $1105 at the hospital level, $14 per treated CDI patient, and $0.11 per admitted patient. In patients with one prior CDI episode, fidaxomicin use was associated with potential savings over 1 year of $1150 at the hospital level, $74 per treated CDI patient, and $0.12 per admitted patient. Savings were driven by a reduced rate of CDI recurrence with fidaxomicin treatment and uptake of fidaxomicin. Sensitivity analyses indicated savings when inputs were varied in most scenarios. Conclusion Budgetary savings can be achieved with fidaxomicin due to reduced CDI recurrence as a result of a superior sustained clinical response. Our results support considering the broader benefits of fidaxomicin, beyond its cost, when making formulary inclusion decisions. Plain Language Summary Clostridioides difficile infection (CDI) is a common hospital-acquired infection that affects about half a million people in the US each year. In some patients who have already had CDI, it can recur. These recurrent infections can be difficult to treat, and they place a burden on the healthcare system. CDI is usually treated with the antibiotics fidaxomicin or vancomycin. Fidaxomicin is as effective as vancomycin for treating CDI but is even more effective than vancomycin at preventing CDI recurrence. However, fidaxomicin is more expensive. In this study, we estimated the impact of replacing vancomycin with fidaxomicin for treating CDI on the budget of a typical US hospital. We estimated that treating 15% of patients with CDI using fidaxomicin in place of vancomycin would save the hospital between $1105 and $1150 in a year. This means that despite the higher cost of fidaxomicin, treating as few as 15% of patients with CDI using fidaxomicin instead of vancomycin can be cost-saving for hospitals.
引用
收藏
页码:111 / 126
页数:16
相关论文
共 50 条
  • [41] COMPARATIVE EFFICACY OF FIDAXOMICIN, VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION: A NETWORK META-ANALYSIS
    Okumura, H.
    Fukushima, A.
    Taieb, V
    Shoji, S.
    English, M.
    VALUE IN HEALTH, 2018, 21 : S222 - S222
  • [42] Clostridioides difficile Infection Treatment and Outcome Disparities in a National Sample of United States Hospitals
    Young, Eric H.
    Strey, Kelsey A.
    Lee, Grace C.
    Carlson, Travis J.
    Koeller, Jim M.
    Reveles, Kelly R.
    ANTIBIOTICS-BASEL, 2022, 11 (09):
  • [43] Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis
    Dai, Jianfeng
    Gong, Jing
    Guo, Rui
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (11) : 1727 - 1737
  • [44] Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection
    Chen, Jiahe
    Gong, Cynthia L.
    Hitchcock, Matthew M.
    Holubar, Marisa
    Deresinski, Stanley
    Hay, Joel W.
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (10) : 1448 - 1454
  • [45] The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin
    Yamaguchi, Tetsuo
    Konishi, Hiroe
    Aoki, Kotaro
    Ishii, Yoshikazu
    Chono, Koji
    Tateda, Kazuhiro
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (05) : 483 - 491
  • [46] Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis
    Jianfeng Dai
    Jing Gong
    Rui Guo
    European Journal of Clinical Pharmacology, 2022, 78 : 1727 - 1737
  • [47] COST-EFFECTIVENESS OF FIDAXOMICIN VERSUS VANCOMYCIN AND METRONIDAZOLE IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION IN SPAIN
    Watt, M.
    de Nigris, E.
    McCrea, C.
    VALUE IN HEALTH, 2017, 20 (09) : A784 - A784
  • [48] Predictors for Treatment Failure With Fidaxomicin (FDX) and Vancomycin (VAN) in Clostridium difficile Infection (CDI)
    Louie, Thomas J.
    Golan, Yoav
    Mullane, Kathleen M.
    Miller, Mark
    Crook, Derrick W.
    Lentnek, Arnold
    Kean, Yin
    Gorbach, Sherwood L.
    GASTROENTEROLOGY, 2012, 142 (05) : S739 - S739
  • [49] REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIDAXOMICIN VS. VANCOMYCIN AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION
    Dubberke, Erik R.
    Puckett, Justin T.
    Obi, Engels N.
    Kamal-Bahl, Sachin
    Desai, Kaushal
    Stuart, Bruce
    Doshi, Jalpa A.
    GASTROENTEROLOGY, 2022, 162 (07) : S157 - S157
  • [50] Efficacy of Fidaxomicin versus Oral Vancomycin for Clostridium Difficile Infection in Solid Organ Transplant Recipients
    Tabriz, M.
    Reticker, A.
    Pettit, N.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S949 - S949